Cardiovascular disease: risk assessment and reduction, including lipid modification

statins. Full details of the evidence and the committee's discussion are in evidence review C: statins: efficacy and adverse effects. Choice of drug based on clinical trials 1.5.8 Be aware that when deciding on lipid-lowering treatment to prevent CVD, drugs are preferred for which there is evidence in clinical trials of a beneficial effect on CVD morbidity and mortality. [2008] Statins and pregnancy 1.5.9 Be aware that statins are contraindicated in pregnancy because of the risk to the unborn child of exposure to statins. [2014, amended May 2023] 1.5.10 Explain that: • statins should be stopped if pregnancy is a possibility • statins should be stopped 3 months before attempting to conceive • statins should not be restarted until breastfeeding is finished. [2014, amended May 2023] 1.6 Lipid-lowering treatment for primary prevention of cardiovascular disease There is a NICE patient decision aid to support discussions about statin treatment to reduce the risk of heart disease and stroke for people without CVD. Also see the sections on optimising statin treatment and assessing response to treatment. Lipid target for people taking statins 1.6.1 For primary prevention of CVD aim for a greater than 40% reduction in non-HDL cholesterol. [May 2023] Optimising lifestyle
